Watch for OPGx-LCA5 Phase 3 dosing initiation in Q4 2026 and subsequent data readouts; OPGx-BEST1 high-dose Cohort 2 data will be the next catalyst for that program. The company has seven AAV-based pipeline programs but no approved products, so clinical execution risk remains high.
Price Chart
Executive Summary
Opus Genetics presented interim clinical data at Retina in Rio 2026 for its two lead gene therapy programs. OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable low-dose Cohort 1 participants, and OPGx-LCA5 demonstrated sustained visual function improvements through 24 months in adults. The Phase 3 trial for OPGx-LCA5 is fully enrolled with dosing expected in Q4 2026.
Key Facts
- OPGx-BEST1: 3 of 4 evaluable participants (75%) in low-dose Cohort 1 showed improved retinal sensitivity by microperimetry.
- OPGx-LCA5: 3 adult participants showed sustained visual acuity and light sensitivity improvements through 24 months; 3 pediatric participants through 6 months.
- OPGx-LCA5 Phase 3 natural history and treatment cohorts are fully enrolled; dosing initiation expected in Q4 2026.
- OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
- Both programs are investigational gene therapies for inherited retinal diseases (IRDs).
Financial Impact
No financial data provided in the release; clinical-stage company with no approved products or revenue.
Risk Factors
- Interim data may not predict final Phase 1/2 or Phase 3 results; small sample sizes (5-6 participants per program).
- OPGx-LCA5 Phase 3 primary endpoint (retinal sensitivity across 16 test locations) has not been validated by prior regulatory precedent.
- No revenue or near-term commercialization path; company is pre-revenue and dependent on financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 27, 2026 today | Insider Cluster | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 23, 2026 4d ago | 144 | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 21, 2026 6d ago | 8-K | $3.82 | awaiting T+60 | — | $3.46 (−9.42%) |
Oct 15, 2026 12d ago | 8-K | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Oct 15, 2026 12d ago | Press Release | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Sep 22, 2026 5w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.46 (−32.95%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.46 (−42.72%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.46 (−39.62%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.46 (−22.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers